HEADER HYDROLASE/HYDROLASE INHIBITOR 13-NOV-19 5QTV TITLE FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(2R,7S)-7-({(2E)-3- TITLE 2 [5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-2- TITLE 3 (TRIFLUOROMETHYL)-2,3,4,5,6,7-HEXAHYDRO-1H-8,11-EPIMINO-1,9- TITLE 4 BENZODIAZACYCLOTRIDECIN-14-YL]CARBAMATE COMPND MOL_ID: 1; COMPND 2 MOLECULE: COAGULATION FACTOR XI; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: COAGULATION FACTOR XI, HEAVY CHAIN; COMPND 5 SYNONYM: FXI,PLASMA THROMBOPLASTIN ANTECEDENT,PTA; COMPND 6 EC: 3.4.21.27; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: F11; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469908; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET14B KEYWDS HYDROLASE, SERINE PROTEASE, BLOOD COAGULATION FACTOR, PROTEIN KEYWDS 2 INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR S.SHERIFF REVDAT 4 12-MAY-21 5QTV 1 REMARK REVDAT 3 18-MAR-20 5QTV 1 JRNL REVDAT 2 26-FEB-20 5QTV 1 JRNL REVDAT 1 29-JAN-20 5QTV 0 JRNL AUTH T.FANG,J.R.CORTE,P.J.GILLIGAN,Y.JEON,H.OSUNA,K.A.ROSSI, JRNL AUTH 2 J.E.MYERS JR.,S.SHERIFF,Z.LOU,J.J.ZHENG,T.W.HARPER, JRNL AUTH 3 J.M.BOZARTH,Y.WU,J.M.LUETTGEN,D.A.SEIFFERT,R.R.WEXLER, JRNL AUTH 4 P.Y.S.LAM JRNL TITL ORALLY BIOAVAILABLE AMINE-LINKED MACROCYCLIC INHIBITORS OF JRNL TITL 2 FACTOR XIA. JRNL REF BIOORG.MED.CHEM.LETT. V. 30 26949 2020 JRNL REFN ESSN 1464-3405 JRNL PMID 31932224 JRNL DOI 10.1016/J.BMCL.2020.126949 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.L.QUAN,P.C.WONG,C.WANG,F.WOERNER,J.M.SMALLHEER, REMARK 1 AUTH 2 F.A.BARBERA,J.M.BOZARTH,R.L.BROWN,M.R.HARPEL,J.M.LUETTGEN, REMARK 1 AUTH 3 P.E.MORIN,T.PETERSON,V.RAMAMURTHY,A.R.RENDINA,K.A.ROSSI, REMARK 1 AUTH 4 C.A.WATSON,A.WEI,G.ZHANG,D.SEIFFERT,R.R.WEXLER REMARK 1 TITL TETRAHYDROQUINOLINE DERIVATIVES AS POTENT AND SELECTIVE REMARK 1 TITL 2 FACTOR XIA INHIBITORS. REMARK 1 REF J.MED.CHEM. V. 57 955 2014 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 24405333 REMARK 1 DOI 10.1021/JM401670X REMARK 1 REFERENCE 2 REMARK 1 AUTH J.J.HANGELAND,T.J.FRIENDS,K.A.ROSSI,J.M.SMALLHEER,C.WANG, REMARK 1 AUTH 2 Z.SUN,J.R.CORTE,T.FANG,P.C.WONG,A.R.RENDINA,F.A.BARBERA, REMARK 1 AUTH 3 J.M.BOZARTH,J.M.LUETTGEN,C.A.WATSON,G.ZHANG,A.WEI, REMARK 1 AUTH 4 V.RAMAMURTHY,P.E.MORIN,G.S.BISACCHI,S.SUBRAMANIAM, REMARK 1 AUTH 5 P.ARUNACHALAM,A.MATHUR,D.A.SEIFFERT,R.R.WEXLER,M.L.QUAN REMARK 1 TITL PHENYLIMIDAZOLES AS POTENT AND SELECTIVE INHIBITORS OF REMARK 1 TITL 2 COAGULATION FACTOR XIA WITH IN VIVO ANTITHROMBOTIC ACTIVITY. REMARK 1 REF J.MED.CHEM. V. 57 9915 2014 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 25405503 REMARK 1 DOI 10.1021/JM5010607 REMARK 1 REFERENCE 3 REMARK 1 AUTH J.R.CORTE,T.FANG,J.J.HANGELAND,T.J.FRIENDS,A.R.RENDINA, REMARK 1 AUTH 2 J.M.LUETTGEN,J.M.BOZARTH,F.A.BARBERA,K.A.ROSSI,A.WEI, REMARK 1 AUTH 3 V.RAMAMURTHY,P.E.MORIN,D.A.SEIFFERT,R.R.WEXLER,M.L.QUAN REMARK 1 TITL PYRIDINE AND PYRIDINONE-BASED FACTOR XIA INHIBITORS. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 25 925 2015 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 25592713 REMARK 1 DOI 10.1016/J.BMCL.2014.12.050 REMARK 1 REFERENCE 4 REMARK 1 AUTH D.J.PINTO,J.M.SMALLHEER,J.R.CORTE,E.J.AUSTIN,C.WANG,T.FANG, REMARK 1 AUTH 2 L.M.SMITH 2ND.,K.A.ROSSI,A.R.RENDINA,J.M.BOZARTH,G.ZHANG, REMARK 1 AUTH 3 A.WEI,V.RAMAMURTHY,S.SHERIFF,J.E.MYERS JR.,P.E.MORIN, REMARK 1 AUTH 4 J.M.LUETTGEN,D.A.SEIFFERT,M.L.QUAN,R.R.WEXLER REMARK 1 TITL STRUCTURE-BASED DESIGN OF INHIBITORS OF COAGULATION FACTOR REMARK 1 TITL 2 XIA WITH NOVEL P1 MOIETIES. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 25 1635 2015 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 25728130 REMARK 1 DOI 10.1016/J.BMCL.2015.01.028 REMARK 1 REFERENCE 5 REMARK 1 AUTH Z.HU,P.C.WONG,P.J.GILLIGAN,W.HAN,K.B.PABBISETTY,J.M.BOZARTH, REMARK 1 AUTH 2 E.J.CRAIN,T.HARPER,J.M.LUETTGEN,J.E.MYERS JR.,V.RAMAMURTHY, REMARK 1 AUTH 3 K.A.ROSSI,S.SHERIFF,C.A.WATSON,A.WEI,J.J.ZHENG,D.A.SEIFFERT, REMARK 1 AUTH 4 R.R.WEXLER,M.L.QUAN REMARK 1 TITL DISCOVERY OF A POTENT PARENTERALLY ADMINISTERED FACTOR XIA REMARK 1 TITL 2 INHIBITOR WITH HYDROXYQUINOLIN-2(1H)-ONE AS THE P2' MOIETY. REMARK 1 REF ACS MED.CHEM.LETT. V. 6 590 2015 REMARK 1 REFN ISSN 1948-5875 REMARK 1 PMID 26005539 REMARK 1 DOI 10.1021/ACSMEDCHEMLETT.5B00066 REMARK 1 REFERENCE 6 REMARK 1 AUTH L.M.SMITH 2ND.,M.J.ORWAT,Z.HU,W.HAN,C.WANG,K.A.ROSSI, REMARK 1 AUTH 2 P.J.GILLIGAN,K.B.PABBISETTY,H.OSUNA,J.R.CORTE,A.R.RENDINA, REMARK 1 AUTH 3 J.M.LUETTGEN,P.C.WONG,R.NARAYANAN,T.W.HARPER,J.M.BOZARTH, REMARK 1 AUTH 4 E.J.CRAIN,A.WEI,V.RAMAMURTHY,P.E.MORIN,B.XIN,J.ZHENG, REMARK 1 AUTH 5 D.A.SEIFFERT,M.L.QUAN,P.Y.S.LAM,R.R.WEXLER,D.J.P.PINTO REMARK 1 TITL NOVEL PHENYLALANINE DERIVED DIAMIDES AS FACTOR XIA REMARK 1 TITL 2 INHIBITORS. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 26 472 2016 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 26704266 REMARK 1 DOI 10.1016/J.BMCL.2015.11.089 REMARK 1 REFERENCE 7 REMARK 1 AUTH J.R.CORTE,T.FANG,D.J.PINTO,M.J.ORWAT,A.R.RENDINA, REMARK 1 AUTH 2 J.M.LUETTGEN,K.A.ROSSI,A.WEI,V.RAMAMURTHY,J.E.MYERS JR., REMARK 1 AUTH 3 S.SHERIFF,R.NARAYANAN,T.W.HARPER,J.J.ZHENG,Y.X.LI, REMARK 1 AUTH 4 D.A.SEIFFERT,R.R.WEXLER,M.L.QUAN REMARK 1 TITL ORALLY BIOAVAILABLE PYRIDINE AND PYRIMIDINE-BASED FACTOR XIA REMARK 1 TITL 2 INHIBITORS: DISCOVERY OF THE METHYL N-PHENYL CARBAMATE P2 REMARK 1 TITL 3 PRIME GROUP. REMARK 1 REF BIOORG.MED.CHEM. V. 24 2257 2016 REMARK 1 REFN ESSN 1464-3391 REMARK 1 PMID 27073051 REMARK 1 DOI 10.1016/J.BMC.2016.03.062 REMARK 1 REFERENCE 8 REMARK 1 AUTH J.R.CORTE,T.FANG,H.OSUNA,D.J.PINTO,K.A.ROSSI,J.E.MYERS JR., REMARK 1 AUTH 2 S.SHERIFF,Z.LOU,J.J.ZHENG,T.W.HARPER,J.M.BOZARTH,Y.WU, REMARK 1 AUTH 3 J.M.LUETTGEN,D.A.SEIFFERT,C.P.DECICCO,R.R.WEXLER,M.L.QUAN REMARK 1 TITL STRUCTURE-BASED DESIGN OF MACROCYCLIC FACTOR XIA INHIBITORS: REMARK 1 TITL 2 DISCOVERY OF THE MACROCYCLIC AMIDE LINKER. REMARK 1 REF J.MED.CHEM. V. 60 1060 2017 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 28085275 REMARK 1 DOI 10.1021/ACS.JMEDCHEM.6B01460 REMARK 1 REFERENCE 9 REMARK 1 AUTH J.R.CORTE,W.YANG,T.FANG,Y.WANG,H.OSUNA,A.LAI,W.R.EWING, REMARK 1 AUTH 2 K.A.ROSSI,J.E.MYERS JR.,S.SHERIFF,Z.LOU,J.J.ZHENG, REMARK 1 AUTH 3 T.W.HARPER,J.M.BOZARTH,Y.WU,J.M.LUETTGEN,D.A.SEIFFERT, REMARK 1 AUTH 4 M.L.QUAN,R.R.WEXLER,P.Y.S.LAM REMARK 1 TITL MACROCYCLIC INHIBITORS OF FACTOR XIA: DISCOVERY OF REMARK 1 TITL 2 ALKYL-SUBSTITUTED MACROCYCLIC AMIDE LINKERS WITH IMPROVED REMARK 1 TITL 3 POTENCY. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 27 3833 2017 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 28687203 REMARK 1 DOI 10.1016/J.BMCL.2017.06.058 REMARK 1 REFERENCE 10 REMARK 1 AUTH C.WANG,J.R.CORTE,K.A.ROSSI,J.M.BOZARTH,Y.WU,S.SHERIFF, REMARK 1 AUTH 2 J.E.MYERS JR.,J.M.LUETTGEN,D.A.SEIFFERT,R.R.WEXLER,M.L.QUAN REMARK 1 TITL MACROCYCLIC FACTOR XIA INHIBITORS. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 27 4056 2017 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 28780160 REMARK 1 DOI 10.1016/J.BMCL.2017.07.048 REMARK 1 REFERENCE 11 REMARK 1 AUTH D.J.P.PINTO,M.J.ORWAT,L.M.SMITH 2ND.,M.L.QUAN,P.Y.S.LAM, REMARK 1 AUTH 2 K.A.ROSSI,A.APEDO,J.M.BOZARTH,Y.WU,J.J.ZHENG,B.XIN, REMARK 1 AUTH 3 N.TOUSSAINT,P.STETSKO,O.GUDMUNDSSON,B.MAXWELL,E.J.CRAIN, REMARK 1 AUTH 4 P.C.WONG,Z.LOU,T.W.HARPER,S.A.CHACKO,J.E.MYERS JR., REMARK 1 AUTH 5 S.SHERIFF,H.ZHANG,X.HOU,A.MATHUR,D.A.SEIFFERT,R.R.WEXLER, REMARK 1 AUTH 6 J.M.LUETTGEN,W.R.EWING REMARK 1 TITL DISCOVERY OF A PARENTERAL SMALL MOLECULE COAGULATION FACTOR REMARK 1 TITL 2 XIA INHIBITOR CLINICAL CANDIDATE (BMS-962212). REMARK 1 REF J.MED.CHEM. V. 60 9703 2017 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 29077405 REMARK 1 DOI 10.1021/ACS.JMEDCHEM.7B01171 REMARK 1 REFERENCE 12 REMARK 1 AUTH C.G.CLARK,K.A.ROSSI,J.R.CORTE,T.FANG,J.M.SMALLHEER, REMARK 1 AUTH 2 I.DE LUCCA,D.S.NIRSCHL,M.J.ORWAT,D.J.P.PINTO,Z.HU,Y.WANG, REMARK 1 AUTH 3 W.YANG,Y.JEON,W.R.EWING,J.E.MYERS JR.,S.SHERIFF,Z.LOU, REMARK 1 AUTH 4 J.M.BOZARTH,Y.WU,A.RENDINA,T.HARPER,J.ZHENG,B.XIN,Q.XIANG, REMARK 1 AUTH 5 J.M.LUETTGEN,D.A.SEIFFERT,R.R.WEXLER,P.Y.S.LAM REMARK 1 TITL STRUCTURE BASED DESIGN OF MACROCYCLIC FACTOR XIA INHIBITORS: REMARK 1 TITL 2 DISCOVERY OF CYCLIC P1 LINKER MOIETIES WITH IMPROVED ORAL REMARK 1 TITL 3 BIOAVAILABILITY. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 29 26604 2019 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 31445854 REMARK 1 DOI 10.1016/J.BMCL.2019.08.008 REMARK 1 REFERENCE 13 REMARK 1 AUTH J.R.CORTE,D.J.P.PINTO,T.FANG,H.OSUNA,W.YANG,Y.WANG,A.LAI, REMARK 1 AUTH 2 C.G.CLARK,J.H.SUN,R.RAMPULLA,A.MATHUR,M.KASPADY, REMARK 1 AUTH 3 P.R.NEITHNADKA,Y.C.LI,K.A.ROSSI,J.E.MYERS JR.,S.SHERIFF, REMARK 1 AUTH 4 Z.LOU,T.W.HARPER,C.HUANG,J.J.ZHENG,J.M.BOZARTH,Y.WU, REMARK 1 AUTH 5 P.C.WONG,E.J.CRAIN,D.A.SEIFFERT,J.M.LUETTGEN,P.Y.S.LAM, REMARK 1 AUTH 6 R.R.WEXLER,W.R.EWING REMARK 1 TITL POTENT, ORALLY BIOAVAILABLE, AND EFFICACIOUS MACROCYCLIC REMARK 1 TITL 2 INHIBITORS OF FACTOR XIA. DISCOVERY OF PYRIDINE-BASED REMARK 1 TITL 3 MACROCYCLES POSSESSING PHENYLAZOLE CARBOXAMIDE P1 GROUPS. REMARK 1 REF J.MED.CHEM. V. 63 784 2020 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 31833761 REMARK 1 DOI 10.1021/ACS.JMEDCHEM.9B01768 REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.6 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 28.70 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 3 NUMBER OF REFLECTIONS : 19769 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.175 REMARK 3 R VALUE (WORKING SET) : 0.174 REMARK 3 FREE R VALUE : 0.202 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.030 REMARK 3 FREE R VALUE TEST SET COUNT : 994 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.000 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.32 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.99 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2831 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.1960 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2686 REMARK 3 BIN R VALUE (WORKING SET) : 0.1930 REMARK 3 BIN FREE R VALUE : 0.2550 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.12 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 145 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1850 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 106 REMARK 3 SOLVENT ATOMS : 198 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 29.07 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 25.99 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -2.90700 REMARK 3 B22 (A**2) : -2.90700 REMARK 3 B33 (A**2) : 5.81400 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.230 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.185 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.153 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.172 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.148 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.946 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.941 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2069 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 2818 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 699 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 41 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 337 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2069 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 255 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2461 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.02 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.83 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 15.38 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5QTV COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 15-NOV-19. REMARK 100 THE DEPOSITION ID IS D_1001402400. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-APR-10 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU FR-E SUPERBRIGHT REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MICROMAX CONFOCAL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU SATURN 92 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19854 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.200 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 10.70 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.15100 REMARK 200 FOR THE DATA SET : 18.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.28 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 10.70 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.51900 REMARK 200 FOR SHELL : 5.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 4TY7 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 64.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.45 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM SODIUM ACETATE, PH 4.6, 25% REMARK 280 (W/V) MEPEG2000, 200 MM AMMONIUM SULFATE, THEN TRANSFERRED TO REMARK 280 100 MM TRIS-HCL, PH 7.0, 25% (W/V) MEPEG2000, 200 MM AMMONIUM REMARK 280 SULFATE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 32 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+1/3 REMARK 290 6555 -X,-X+Y,-Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 70.73333 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 35.36667 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 35.36667 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 70.73333 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 S SO4 A 303 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 HIS A 246 REMARK 465 HIS A 247 REMARK 465 HIS A 248 REMARK 465 HIS A 249 REMARK 465 HIS A 250 REMARK 465 HIS A 251 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 78 CG CD OE1 OE2 REMARK 470 LYS A 126 CG CD CE NZ REMARK 470 ASP A 128 CG OD1 OD2 REMARK 470 ASN A 130 CG OD1 ND2 REMARK 470 ARG A 148 CG CD NE CZ NH1 NH2 REMARK 470 ARG A 172 CG CD NE CZ NH1 NH2 REMARK 470 GLU A 185 CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 149 -148.29 -153.61 REMARK 500 SER A 214 -71.46 -120.32 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue QLS A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 A 302 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 A 303 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 304 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 305 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 306 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 307 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 308 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 309 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 310 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 311 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 312 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 313 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 314 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 315 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 316 DBREF 5QTV A 16 245 UNP P03951 FA11_HUMAN 388 625 SEQADV 5QTV GLY A 113 UNP P03951 ASN 491 CONFLICT SEQADV 5QTV GLY A 115 UNP P03951 THR 493 CONFLICT SEQADV 5QTV HIS A 246 UNP P03951 EXPRESSION TAG SEQADV 5QTV HIS A 247 UNP P03951 EXPRESSION TAG SEQADV 5QTV HIS A 248 UNP P03951 EXPRESSION TAG SEQADV 5QTV HIS A 249 UNP P03951 EXPRESSION TAG SEQADV 5QTV HIS A 250 UNP P03951 EXPRESSION TAG SEQADV 5QTV HIS A 251 UNP P03951 EXPRESSION TAG SEQRES 1 A 244 ILE VAL GLY GLY THR ALA SER VAL ARG GLY GLU TRP PRO SEQRES 2 A 244 TRP GLN VAL THR LEU HIS THR THR SER PRO THR GLN ARG SEQRES 3 A 244 HIS LEU CYS GLY GLY SER ILE ILE GLY ASN GLN TRP ILE SEQRES 4 A 244 LEU THR ALA ALA HIS CYS PHE TYR GLY VAL GLU SER PRO SEQRES 5 A 244 LYS ILE LEU ARG VAL TYR SER GLY ILE LEU ASN GLN SER SEQRES 6 A 244 GLU ILE LYS GLU ASP THR SER PHE PHE GLY VAL GLN GLU SEQRES 7 A 244 ILE ILE ILE HIS ASP GLN TYR LYS MET ALA GLU SER GLY SEQRES 8 A 244 TYR ASP ILE ALA LEU LEU LYS LEU GLU THR THR VAL GLY SEQRES 9 A 244 TYR GLY ASP SER GLN ARG PRO ILE CYS LEU PRO SER LYS SEQRES 10 A 244 GLY ASP ARG ASN VAL ILE TYR THR ASP CYS TRP VAL THR SEQRES 11 A 244 GLY TRP GLY TYR ARG LYS LEU ARG ASP LYS ILE GLN ASN SEQRES 12 A 244 THR LEU GLN LYS ALA LYS ILE PRO LEU VAL THR ASN GLU SEQRES 13 A 244 GLU CYS GLN LYS ARG TYR ARG GLY HIS LYS ILE THR HIS SEQRES 14 A 244 LYS MET ILE CYS ALA GLY TYR ARG GLU GLY GLY LYS ASP SEQRES 15 A 244 ALA CYS LYS GLY ASP SER GLY GLY PRO LEU SER CYS LYS SEQRES 16 A 244 HIS ASN GLU VAL TRP HIS LEU VAL GLY ILE THR SER TRP SEQRES 17 A 244 GLY GLU GLY CYS ALA GLN ARG GLU ARG PRO GLY VAL TYR SEQRES 18 A 244 THR ASN VAL VAL GLU TYR VAL ASP TRP ILE LEU GLU LYS SEQRES 19 A 244 THR GLN ALA VAL HIS HIS HIS HIS HIS HIS HET QLS A 301 71 HET SO4 A 302 5 HET SO4 A 303 5 HET EDO A 304 4 HET EDO A 305 4 HET EDO A 306 4 HET EDO A 307 4 HET EDO A 308 4 HET EDO A 309 4 HET EDO A 310 4 HET EDO A 311 4 HET EDO A 312 4 HET EDO A 313 4 HET EDO A 314 4 HET EDO A 315 4 HET EDO A 316 4 HETNAM QLS METHYL [(2R,7S)-7-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1- HETNAM 2 QLS YL)PHENYL]PROP-2-ENOYL}AMINO)-2-(TRIFLUOROMETHYL)-2,3, HETNAM 3 QLS 4,5,6,7-HEXAHYDRO-1H-8,11-EPIMINO-1,9- HETNAM 4 QLS BENZODIAZACYCLOTRIDECIN-14-YL]CARBAMATE HETNAM SO4 SULFATE ION HETNAM EDO 1,2-ETHANEDIOL HETSYN EDO ETHYLENE GLYCOL FORMUL 2 QLS C28 H27 CL F3 N9 O3 FORMUL 3 SO4 2(O4 S 2-) FORMUL 5 EDO 13(C2 H6 O2) FORMUL 18 HOH *198(H2 O) HELIX 1 AA1 ALA A 55 TYR A 58B 5 6 HELIX 2 AA2 SER A 62 LYS A 64 5 3 HELIX 3 AA3 ASN A 72 ILE A 76 5 5 HELIX 4 AA4 MET A 96 GLY A 100 5 5 HELIX 5 AA5 LYS A 126 VAL A 131 5 6 HELIX 6 AA6 THR A 164 TYR A 171 1 9 HELIX 7 AA7 TYR A 234 GLN A 243 1 10 SHEET 1 AA1 8 THR A 20 ALA A 21 0 SHEET 2 AA1 8 GLN A 156 LYS A 159 -1 O LYS A 157 N THR A 20 SHEET 3 AA1 8 CYS A 136 GLY A 140 -1 N GLY A 140 O GLN A 156 SHEET 4 AA1 8 PRO A 198 HIS A 203 -1 O SER A 200 N TRP A 137 SHEET 5 AA1 8 VAL A 206 TRP A 215 -1 O VAL A 206 N HIS A 203 SHEET 6 AA1 8 GLY A 226 ASN A 230 -1 O VAL A 227 N TRP A 215 SHEET 7 AA1 8 MET A 180 ALA A 183 -1 N ILE A 181 O TYR A 228 SHEET 8 AA1 8 LEU A 162 VAL A 163 -1 N VAL A 163 O CYS A 182 SHEET 1 AA2 7 GLN A 30 THR A 35 0 SHEET 2 AA2 7 ARG A 39 GLY A 48 -1 O LEU A 41 N LEU A 33 SHEET 3 AA2 7 TRP A 51 THR A 54 -1 O LEU A 53 N SER A 45 SHEET 4 AA2 7 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 5 AA2 7 PHE A 83 ILE A 90 -1 N ILE A 89 O LEU A 105 SHEET 6 AA2 7 LEU A 65A TYR A 67 -1 N VAL A 66 O PHE A 83 SHEET 7 AA2 7 GLN A 30 THR A 35 -1 N HIS A 34 O ARG A 65B SSBOND 1 CYS A 42 CYS A 58 1555 1555 2.02 SSBOND 2 CYS A 136 CYS A 201 1555 1555 2.05 SSBOND 3 CYS A 168 CYS A 182 1555 1555 2.03 SSBOND 4 CYS A 191 CYS A 219 1555 1555 2.06 CISPEP 1 SER A 36A PRO A 36B 0 3.04 SITE 1 AC1 24 ARG A 39 HIS A 40 LEU A 41 HIS A 57 SITE 2 AC1 24 LEU A 147 ILE A 151 ASP A 189 ALA A 190 SITE 3 AC1 24 CYS A 191 LYS A 192 GLY A 193 ASP A 194 SITE 4 AC1 24 SER A 195 TRP A 215 GLY A 216 GLY A 218 SITE 5 AC1 24 CYS A 219 GLY A 226 VAL A 227 EDO A 304 SITE 6 AC1 24 EDO A 307 EDO A 316 HOH A 482 HOH A 528 SITE 1 AC2 10 VAL A 23 ARG A 24 GLY A 25 GLU A 26 SITE 2 AC2 10 TRP A 27 PRO A 28 ILE A 70 LEU A 155 SITE 3 AC2 10 HOH A 413 HOH A 435 SITE 1 AC3 3 LYS A 169 ARG A 170 ARG A 184B SITE 1 AC4 5 QLS A 301 EDO A 307 EDO A 308 EDO A 316 SITE 2 AC4 5 HOH A 492 SITE 1 AC5 5 ASN A 49 THR A 111 VAL A 112 GLY A 113 SITE 2 AC5 5 TYR A 114 SITE 1 AC6 6 ARG A 24 SER A 99 GLY A 173 LYS A 175 SITE 2 AC6 6 HOH A 484 HOH A 489 SITE 1 AC7 9 SER A 81 LEU A 147 GLY A 216 GLU A 217 SITE 2 AC7 9 GLY A 218 QLS A 301 EDO A 304 EDO A 308 SITE 3 AC7 9 HOH A 469 SITE 1 AC8 6 GLY A 216 GLU A 217 EDO A 304 EDO A 307 SITE 2 AC8 6 HOH A 427 HOH A 491 SITE 1 AC9 1 HIS A 178 SITE 1 AD1 2 ILE A 76 HOH A 410 SITE 1 AD2 7 GLU A 167 ARG A 170 GLY A 184 TYR A 184A SITE 2 AD2 7 GLU A 223 PRO A 225 HOH A 438 SITE 1 AD3 5 HIS A 178 MET A 180 ILE A 181 ASN A 230 SITE 2 AD3 5 HOH A 532 SITE 1 AD4 5 SER A 99 GLY A 100 TYR A 101 THR A 177 SITE 2 AD4 5 LYS A 179 SITE 1 AD5 4 GLU A 26 TRP A 137 LYS A 157 HOH A 440 SITE 1 AD6 5 ILE A 47 LEU A 239 THR A 242 GLN A 243 SITE 2 AD6 5 HOH A 433 SITE 1 AD7 6 GLY A 113 TYR A 114 QLS A 301 EDO A 304 SITE 2 AD7 6 HOH A 470 HOH A 492 CRYST1 78.800 78.800 106.100 90.00 90.00 120.00 P 32 2 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012690 0.007327 0.000000 0.00000 SCALE2 0.000000 0.014654 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009425 0.00000